This paper also shows that NAT10 small molecule inhibitors can inhibit tumour proliferation, and therefore the targeted inhibition of NAT10 may be a potential treatment for ccRCC in the future. This evidence concerns the gene NAT10 and nonpapillary renal cell carcinoma.